RNS Number:3073D
BioProgress PLC
05 September 2007


For Immediate Release                                          5 September 2007

                                BioProgress plc

                                Pipeline Update


London, UK, 5 September 2007: BioProgress plc ('BioProgress' or the 'Company')
(AIM: BPRG), the specialty pharmaceutical and OTC product healthcare company,
provides an update to its previous product development announcement released on
31 May 2007.


BioProgress has eleven integrated enabling delivery technologies with
pharmaceutical and OTC healthcare applications. The Company has in development
over 45 patent protected products (an increase from the previous 30) which
utilize these core enabling systems. These developments are either BioProgress's
own product developments or from working with partners.


Since the last update, BioProgress has successfully completed a validation of
the FastWrap concept, a fast dissolving tablet technology using the TabWrapTM
enabling system. Significant technical data has been generated which clearly
shows its superiority over other established pharmaceutical technologies.


In addition, the Company has launched XLWrap, again using the TabWrapTM enabling
system in order to create modified release products. BioProgress has one product
in development with a further three products being targeted for partnering
during 2008 whose branded equivalent sales are in excess of $4 billion sitting
within the analgesic and gastro-intestinal markets.


The developments can be divided into three main categories:


1.       Line extensions for acquired pharmaceutical brands;

2.       Innovative Products suitable for out-licensing or for sale by Dexo
         BioPharm; and

3.       OTC and Nutritional Products;



1.       Line extensions for acquired Pharmaceutical Brands



Collunovar OraDisc


Further to the previously announced licensing agreement with Uluru Inc,
BioProgress is expected to file for regulatory approval of the OraDiscTM B
product during Q4 2007. The product is planned to be launched under the
Collunovar brand in certain European countries.


OraDiscTM B is a product developed from Uluru's adhesive film technology which
incorporates 15 milligrams of benzocaine for the treatment of oral pain. The
product is designed to adhere to the mucosal surface and selectively deliver
pain relief to a localised area. Compared with currently marketed gel products,
OraDiscTM B is designed to provide a significantly greater period of pain relief
as the adhesive film is designed to erode over a 1 - 1.5 hour period. The market
for oral pain relief in the United Kingdom alone is estimated at approximately
$60million. Based upon similar product launches, BioProgress expects penetration
rates in core EU, CIS and Middle Eastern markets to reach approximately 12%
within the first three years of product launch with peak annual sales in excess
of #25m.


RocGelTM


RocGelTM, a gastro-intestinal brand acquired from ToniPharm, is currently
exceeding growth expectations with current growth rates at over 29%. The brand,
due to its exceptional promotional response, has accelerated the development and
scale up of DBP272, DBP276 and DBP278 using the Company's SoluPol technology.
The products are planned to be filed with different regulatory authorities
during H2 2008. Commercialisation and partner programs for these products have
commenced throughout the world.


BioProgress is expecting that its core SoluPol product developments in the
Gastro-Intestinal market will reach peak annual sales from regulatory approval
of over $100m. BioProgress intends to market the brand as RocGelTM on a Global
basis. DBP272 is also being planned to be partnered in Western Europe and within
the US.


In addition to the previously announced development within the gastro-intestinal
field, BioProgress has commenced the development of an enhanced generic version
of a blockbuster gastrointestinal product using its XLWrap technology platform.
The product will be available for both prescription and OTC use. The product is
in partnership discussions for US market.


BioProgress believes that its can generate up to $200m annual revenues
gastro-intestinal franchise in its major territories.


Ah-Chew


Ah-Chew is a range of products within the US market that are categorised as DESI
products, products that do not require any pre-FDA approval. These products are
currently being converted to utilise the FastWrap and Meltums enabling systems
for a variety of combinations as well as the previously announced developments
using the SoluleavesTM technology.


Due to the high barriers to competition regarding the Company's patented
systems, BioProgress believes that it will achieve an additional $15-20m in
sales during the 2008-2009 winter seasons.


With the patented systems around the Ah-Chew developments, BioProgress's profile
as an innovative product development partner is currently being raised.
Additional revenue is expected to be generated, including development income and
supply agreements within the DESI category throughout 2008 and beyond. The
Company is targeting contract revenues in excess of $30m per annum to third
party companies within the US.


2.       Innovative Products suitable for out-licensing or for sale by Dexo
BioPharm


In addition to its current partner programs, BioProgress is focusing on several
areas that are able to generate substantial revenue from its innovative
products. It is concentrating its efforts in the analgesic, cough/cold and
gastro-intestinal (including nausea) markets, both in the prescription and OTC
markets. Non-core innovations are currently either in or are planned to be in
partnership programs where BioProgress will seek to focus on long term supply
and revenue sharing agreements. Additional income is being generated from
licensing and development revenues within the partnership program.





DBP117 - Anti-Migraine


As previously announced, BioProgress is developing a triptan drug within its
SoluleavesTM and WafertabTM technology platforms. New manufacturing techniques
have been developed, taken from the development work carried out on its DBP121
smoking cessation program. The product is entering into commercial scale up
during Q4 2007. It is anticipated that revenues will be generated from
partnership deals early in 2008.


From new market assessments and data, BioProgress has increased its revenue
expectations to reach 3% of the global $3.1billion triptan market, increased
from 1-1.5%



DBP118 - Anti-emesis


The development program is currently on track in line with the Company's
expectations which are that the product will enter into pharmacokinetic studies
during 2008 with the product being filed using the NDA 505 (b) (2) regulatory
pathway. Significant partnership interest has been generated from both the Far
East and Eastern Europe. The Company is expecting peak sales revenues to be in
the region of $32-40m per annum.


DBP121 - Anti Smoking


Using an innovative patented solution to the technical challenges of nicotine
replacement therapy, BioProgress is on track with its development and
partnership program and looks forward to updating the market in due course.


In addition to the SoluleavesTM/ WaferTabTM technology, BioProgress is pleased
to announce the successful formulation of a MeltumsTM formulation which is
designed to release the nicotine over a 10-15 minute period in order to maximise
the absorption of nicotine. The product is designed to be complimentary to the
existing thin strip development and forms part of the commercialisation and
partnership program.


The development of two innovative dosage forms using BioProgress technology in
this area increases the value proposition to partners. With the unique
manufacturing requirements of this technology, long term supply agreements are
at the core of the partnership programs generating long term sustainable
revenues to the business. Such supply revenues could reach in excess of $500m
over a 10 year period.





DBP167 - Novel Analgesic


BioProgress has made significant progress in the development of rapid release
products. Initially, DBP167 was developed for breakthrough pain. Due to its
success and its core focus on pain, the product has been positioned for a range
of line extensions. These utilise the full range of the Company's enabling
systems including:


   *NRobeTM
   *FastWrap
   *XLWrap
   *SoluPol
   *Meltums


In addition to the basic analgesic product, additional combinations are planned
including the addition of decongestants such as phenlyephrine, the only systemic
decongestant available OTC. Work has commenced to create a first in class cough/
cold remedy using this technology.


The product range will be targeted for both prescription and OTC use. The first
product will be submitted to the EU regulatory authorities in early Q4 2007,
ahead of schedule. This product, which creates a novel liquid preparation, is
being targeted for the relief of acute pain especially that associated with
headache and migraine. The product does not contain opiate analgesia and
therefore removes the issues around potential abuse and rebound headaches.


This range is a premium analgesic range, with unique properties that the current
leading brands are unable to compete with. Clinical data supporting the product
is strong showing a speed of onset of analgesia in just a few minutes. The
Company believes that this unique selling point, as well as the ability to
create patient friendly products that ease issues around swallowing, are primary
market drivers.


BioProgress has over the next five years committed to a strong development and
commercialisation program regarding this technology. The core market, apart from
Europe, will be the United States, Japan and China. The range will be extended
into the Dexo US cough/cold prescription franchise with a range of patented
products. The Company believes that its annual peak sales value on a global
basis will be in excess of $300m with all of the different variants. Revenue
will be generated from partner income - milestones and supply agreements - which
will be used to promote the brands in its core territories.



3. OTC and Nutritional Products


The acquisition of Melbrosin in June 2007 has increased the number of product
developments within the nutritional, herbal and Vitamin Mineral Supplement (VMS)
categories. In addition, with the exclusive relationship with the Christian
Doppler Institute in Vienna, BioProgress has access to a unique pipeline to
integrate its enabling systems with natural based medicines.


The Company is currently integrating the Kudos range of products into the German
market for sale through its own sales and marketing business unit. According to
a recent survey conducted by Apotheken Umschau, six out of ten Germans would
prefer their doctor to prescribe them a herbal remedy rather than a synthetic
medicine. The study, involving 1978 Germans, found that more that four-fifths of
the participants - 83.5% - felt that the importance of herbal medicines would
increase.


BioProgress is successfully working with the Melbrosin team to integrate its
core technologies such as TabWrapTM, Meltums and SoluleavesTM into a range of
herbal products that can be both prescribed and sold over the counter.


The Kudos lifestyle range has been complemented with the successful development
and launch of a novel topical product for the treatment of cellulite. The
patented formulation highlights the versatility of the product development team
and its ability to take a product from concept to sales in record time.


In addition, using the recently generated FastWrapTM scientific data,
BioProgress has increased the range of products within the analgesic and cough/
cold therapeutic areas in development. The Global OTC market for analgesics and
cough/cold products is worth $16.7 billion per annum. Due to the innovation of
this novel patented pharmaceutical technology, BioProgress has increased its
expectations to achieve sales penetration rates of 2.5 per cent of the relevant
market share.


The first European TabWrapTM product will be launched in Spring 2008 in Germany.
This product is a different analgesic product to DBP216 and will have a superior
FastWrapTM version available later in the year. The Company believes that it
will achieve Euro6-12 million peak annual sales within the German market alone.
Launches, subject to regulatory approval, are expected in other Dexo
subsidiaries.





Other Development Programs


BioProgress is focussed on delivering its development program. Significant work
and forward planning has occurred ensuring that BioProgress has the
manufacturing capability to fulfil its sales expectations. New manufacturing
techniques, and additional recent advances in improving the film itself, ensure
that the Company is able to meet its current film requirements.


The Company has made a quantum leap in its knowledge of product formulation
using soluble polymers. As a consequence of its own programme and significant
diligence issues, BioProgress terminated its proposed completion of the
in-licensing of MuGard from Access Inc. The decision was made due also to the
advances with the Company's own SoluPol system. This action saved the Company
significant capital expenditure which is being placed into its own development
program where the Company makes high operating and net margins.


Since the previous product development update, BioProgress has seen the
validation of its technology with the registration of two medical devices with
HypozalixTM, the Group's artificial saliva product.






Steve Martin, Chief Development Officer, BioProgress PLC said:


"The Company is now at the strongest point it has ever been, with a depth of
product development that is both low risk, low development spend but highly
desirable within the global marketplace. The Company is generating revenues from
its development and licensing program, a key validation of our intellectual
property.


Through the generation of robust scientific data, the Company has worked hard to
ensure that it is able to create sustainable ongoing revenues, and looks forward
to maximising shareholder value."



For further information:

BioProgress Plc                                   + 44 (0) 20 7098 9881
Richard Trevillion, CEO
Steve Martin, CDO
Hiral Patel, CFO

Buchanan Communications                           + 44 (0) 20 7466 5000
Rebecca Skye Dietrich/Mark Court


About BioProgress

BioProgress plc is an innovative specialty pharmaceutical and healthcare
business based around its platform technologies in polymer and film systems.
Listed on London's AIM in May 2003, The company has over 80 patents granted or
in application within 24 patent families and has product development agreements
and strategic alliances with several global companies. As a virtually integrated
business, BioProgress has acquired sales and marketing resources within Europe
and the US as a launch mechanism for its own pharmaceutical products. The
business continues to develop innovative delivery mechanisms using its XGELTM
polymer technology. For further information please go to www.bioprogress.com


Forward-Looking Information

The Ordinary Shares of BioProgress plc are registered under the US Securities
and Exchange Act of 1934.  To the extent that this announcement contains certain
"forward-looking statements" within the meaning of the Private Securities
Litigation Reform Act of 1995, this paragraph applies.  These statements are
based on management's current expectations and are subject to uncertainty and
changes in circumstances.  Actual results may vary materially from the
expectations contained in the forward-looking statements.  The forward-looking
statements in this release include statements addressing future financial and
operating results and the timing and benefits of the reorganisation.  Detailed
information about factors pertinent to the business of the company that could
cause actual results to differ is set forth in the Company's filings with the
Securities and Exchange Commission.  The Company is under no obligation to (and
expressly disclaim any such obligation to) update or alter its forward-looking
statements whether as a result of new information, future events or otherwise.
This announcement is for information only and does not constitute an offer or
invitation to acquire or dispose of any securities or investment advice.  The
distribution of the announcement and/or issue of securities in certain
jurisdictions may be restricted by law.  Persons into whose possession this
announcement comes are required to inform themselves about and to observe such
restrictions.










                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
DRLLIMPTMMTMBFR
Bioprogress (LSE:BPRG)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Bioprogress Charts.
Bioprogress (LSE:BPRG)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Bioprogress Charts.